(A) CT (B) PET and (C) fused PET/CT of 68Ga-Ga-PSMA-11 PET scan of a patient with distant osseous metastases in the right proximal femur, visible on PET with intermediate PSMA uptake (SUVmax = 7.8) and missed by CT, confirmed later on follow-up CT imaging.
(A) CT (B) PET and (C) fused PET/CT of 68Ga-Ga-PSMA-11 PET scan of a patient with distant osseous metastases in the right proximal femur, visible on PET with intermediate PSMA uptake (SUVmax = 7.8) and missed by CT, confirmed later on follow-up CT imaging. Image created by WP Fendler, P Fragoso Costa and N Hirmas, et al., Essen University Hospital, Essen, Germany.

October 18, 2021 — PSMA (prostate-specific membrane antigen) PET/CT is  more accurate than conventional CT in the detection of hepatocellular carcinoma metastases, according to research published in the September issue of The Journal of Nuclear Medicine. PSMA PET imaging was also found to be associated with a change of management for nearly half of the patients, allowing them to receive the most effective treatment for their disease.

Hepatocellular carcinoma—a type of liver cancer—is the sixth most prevalent cancer and the third most frequent cause of cancer-related death. Despite the availability of a growing number of local and systemic therapies, patient survival remains short. Accurate staging is critical for management decisions. 

“With more accurate imaging for staging of patients, we can identify early on patients who could benefit from particular treatments, like chemotherapy, which has an impact on survival and quality of life,” said Nader Hirmas, M.D., physician scientist at the department of nuclear medicine at Essen University Hospital in Essen, Germany.

Hepatocellular carcinoma is typically diagnosed with conventional imaging, like CT or MRI. Recent research, however, has shown that hepatocellular carcinoma has PSMA on the surface of its cancer cells. To explore this discovery, study authors assessed the impact of PSMA PET imaging on patients with hepatocellular carcinoma and compared it to CT.

The retrospective study included 40 patients who received imaging with 68Ga-Ga-PSMA-11 PET/CT. Patients received a CT as well as a PSMA PET scan. Three blinded nuclear medicine physicians determined the presence of hepatocellular carcinoma in the liver and elsewhere in the body based on the CT images and the PSMA PET images separately, and lesions were validated by follow-up imaging or biopsy. Researchers then compared the detection rates for each imaging modality, as well as changes made in staging, grouping and management plans of patients.

Results indicate that PSMA PET and CT are similar in diagnosing hepatocellular carcinoma in the liver, but that PSMA PET is more accurate for tumors that have spread beyond the liver. With a more accurate diagnosis of the locations of the hepatocellular carcinoma tumors, the original management plan changed in 19 of the 40 patients—almost half of the patient sample—leading towards a shift towards systemic therapy.

“We hope that this study encourages more research into the topic, so that multi-disciplinary oncology practices and guidelines would use PSMA PET in the diagnosis of hepatocellular carcinoma,” noted Wolfgang Fendler, M.D., vice chair of nuclear medicine at the Essen University Hospital in Essen, Germany. “More broadly, it shows that many of the molecular imaging techniques could supplement or even outperform conventional imaging in the diagnosis of particular tumors.”

For more information: www.snmmi.org

Related Content

News | Nuclear Imaging

November 22, 2021 — IBA, a leader in particle accelerator technology, and NorthStar Medical Radioisotopes LLC, a global ...

Time November 22, 2021
arrow
Videos | Radiation Oncology

Walter Curran, Jr. M.D., FACR, FASCO, GenesisCare global chief medical officer, discusses three technologies that are ...

Time November 16, 2021
arrow
News | Digital Pathology

November 15, 2021 — Saltus Biotech, a leader in 8k image technology, introduces a new high-end computer workstation and ...

Time November 15, 2021
arrow
Sponsored Content | Case Study | Enterprise Imaging

Reporting produces the tangible work product of diagnostic radiologists. Reports should reflect the expertise of the ...

Time November 05, 2021
arrow
News | PET Imaging

November 1, 2021 — Researchers in the U.S. and Japan have demonstrated the first experimental cross-sectional medical ...

Time November 01, 2021
arrow
News | Coronavirus (COVID-19)

November 1, 2021 — Long-term cognitive problems after a COVID-19 diagnosis may be a result of fatigue rather than ...

Time November 01, 2021
arrow
News | Molecular Imaging

October 29, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time October 29, 2021
arrow
News | Radiation Oncology

October 20, 2021 — RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy (BgRT) as a ...

Time October 20, 2021
arrow
News | Radiation Therapy

October 19, 2021 — RAD Technology Medical Systems (RAD) announced that it will be exhibiting at the 2021 American ...

Time October 19, 2021
arrow
News | PET Imaging

October 19, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 19, 2021
arrow
Subscribe Now